Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal
Most Observers Still Want More Detailed Data From Urothelial Cancer Study
Seagen/Astellas announced Phase Ib/II trial data for the combination that could lead to an accelerated approval for the antibody-drug conjugate in first-line bladder cancer.
You may also be interested in...
The main Japanese pharma players report a generally strong fiscal Q1, helped by mainstays including Daiichi Sankyo's Enhertu, Astellas's Xtandi and Padcev and Chugai's Actemra, and in some cases by the weaker yen.
The Seattle-based biotech reported a 24% increase in product sales in the second quarter amid speculation that Merck is about to acquire the company.
Keytruda- and Gardasil-driven revenue growth exceeded forecasts and Merck expects to keep the PD-1 blockbuster cash coming with earlier-stage indications and a potential subcutaneous formulation.